In an editorial for the Annals of the American Thoracic Society, Joe K. Gerald, MD, PhD, associate professor at the University of Arizona Mel and Enid Zuckerman College of Public Health, reviews the state of generic alternatives for orally inhaled medications commonly prescribed to patients with asthma.
[Photo: Dr. Joe K. Gerald]
No generic alternatives for inhalers are currently marketed in the United States. Because generic medications are less expensive, unleashing generic competition should yield substantial savings for third-party payers, government programs, and patients.
Prescription medication sales account for one-third of all asthma-related medical expenditures in the U.S. Due in part to cost-sharing requirements for prescription medications, approximately 20% of patients with asthma spend more than 10% of their income on medical care, a common measure of financial hardship.
The full article is available in the current issue:
Generic Competition for Orally Inhaled Respiratory Medications. Two Steps Forward, One Step Back
Editorial by Joe K. Gerald
Annals of the American Thoracic Society. February 1, 2017